Sign in to view content

Phase 3 Randomized, Double-Masked Studies of Brolucizumab Versus Aflibercept in nAMD: Expanded Primary and Secondary Outcomes From HAWK/HARRIER

Arshad M. Khanani, MD, MA, FASRS

Video
Published 2018

Related

Randomized Trial of Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: 5-Year Outcomes
Jeffrey G. Gross, MD, FASRS
Annual Meeting Talks
2018
Two-Year Results From the Subretinal RGX-314 Gene Therapy Phase 1/2a Study for the Treatment of Neovascular AMD
Robert L. Avery, MD
Updates from the Field
2021
Elamipretide, a Mitochondria-Targeted Drug for the Treatment of Vision Loss
Scott W. Cousins, MD
Updates from the Field
2019

Category: Age-Related Macular Degeneration

See more